Skip to main content
Premium Trial:

Request an Annual Quote

Merrimack Gets Second Phase I SBIR Grant, for Antibody Arrays

NEW YORK, March 25 (GenomeWeb News) - Merrimack Pharmaceuticals has received a second Phase I SBIR grant from the National Cancer Institute to develop protein microarrays, the company said today.

 

The grant supports the development of antibodies for microarrays using yeast display technology. Merrimack plans to use these antibody arrays to study protein networks in signaling pathways associated with cancer and autoimmune diseases.

 

In January, Cambridge, Mass.-based Merrimack received another Phase I SBIR grant from the NCI to develop microarray technology to study apoptosis and cancer.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.